Wells Fargo Initiates Coverage On Cabaletta Bio with Overweight Rating, Announces Price Target of $17

Benzinga | Dec 8, 2021 7:26 AM EST

Wells Fargo Initiates Coverage On Cabaletta Bio with Overweight Rating, Announces Price Target of $17

Wells Fargo analyst Derek Archila initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Overweight rating and announces Price Target of $17.